SYNAIRGEN LIMITED
Company number 05233429 · Monitor this company
Executive summary
Synairgen has recently transitioned from a public to a private company under the majority control of TFG Asset Management, fundamentally altering its capital structure and funding dynamics. The absence of quantitative financial data prevents a standalone credit assessment, necessitating a conditional opinion reliant on verified parent company support. Given the high cash burn typical of biotech R&D, ongoing monitoring must focus on the explicitness of TFG's financial backing and the company's cash runway.
Overview
- Company type
- Private Limited Company
- Incorporated
- 2004-09-16
- Registered office
- Frobisher House 2nd Floor, Nelson Gate, Southampton, England, SO15 1GX
- Postcode
- SO15 1GX
- Capital
- 11 GBP
- Accounts category
- Group
Accounts
- Last made up to
- 2025-12-31
- Next due by
- 2027-09-30
- Financial year end
- 31 December
Confirmation statement
- Last statement dated
- 2025-09-16
- Next due by
- 2026-09-30
Nature of business (SIC)
- 72110 Research and experimental development on biotechnology
Officers 5 current · 15 resigned
Group structure 1 subsidiary
From persons-with-significant-control filings on the public register.
Contact details
- Website
- synairgen.com
A drug discovery company specialising in respiratory diseases with a focus on asthma and chronic obstructive pulmonary disease (COPD)
Previous company names
| Name | Date changed |
|---|---|
| SYNAIRGEN PLC | 2025-05-19 |
| SYNAIRGEN RESEARCH PLC | 2004-10-12 |
Previous registered addresses 1
| Address | Changed on |
|---|---|
| 2 VENTURE ROAD, CHILWORTH SCIENCE PARK, SOUTHAMPTON, SO16 7NP | 2007-06-17 |
Among its peers
Among the oldest 25%
of 35 similar companies in SO, trading since 2004
The class of 2004
37%
of the 135,820 companies incorporated in 2004 are still active today; 61% have since been dissolved.
A fact about the year, not a forecast for this company.